Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery (NCT04730609) | Clinical Trial Compass
RecruitingPhase 4
Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery
United States40 participantsStarted 2021-09-21
Plain-language summary
The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women presenting for planned cesarean delivery.
* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
* Singleton gestation in the 3rd trimester (28-42 weeks gestation).
* Spinal anesthesia technique Women presenting for planned cesarean delivery.
* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
* Singleton gestation in the 3rd trimester (28-42 weeks gestation).
* Spinal anesthesia technique.
Exclusion Criteria:
* Any contraindication to spinal anesthesia technique.
* Allergy or intolerance to dexmedetomidine or clonidine.
* Oral temperature \< 36Ā° Celsius prior to procedure.
* Unable to give personal consent.
* PPROM or concern for infection (e.g., chorioamnionitis).
* Conversion to General Anesthesia prior to randomization.
* Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.
What they're measuring
1
Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan
Timeframe: 5 minutes after administration of the drug